RT Journal Article SR Electronic T1 In Vitro Generation of Murine Dendritic Cells for Cancer Immunotherapy: An Optimized Protocol JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 5793 OP 5801 VO 36 IS 11 A1 THAÏS BAERT A1 ABHISHEK D. GARG A1 EVA VINDEVOGEL A1 ANAÏS VAN HOYLANDT A1 GODELIEVE VERBIST A1 PATRIZIA AGOSTINIS A1 IGNACE VERGOTE A1 AN COOSEMANS YR 2016 UL http://ar.iiarjournals.org/content/36/11/5793.abstract AB Background/Aim: Dendritic cell (DC) immunotherapy induces tumor-reactive T-cells. We optimized the maturation of murine DC against ovarian cancer. Materials and Methods: Immature DC were generated from bone-marrow progenitor cells and loaded with hypericin-photodynamic-treated (Hyp-PDT) tumor cells (primary maturation). Lipopolysacharide (LPS 1 μg/ml) was used as a secondary maturation stimulus. After 24 h, maturation was assessed using flow cytometry. For in vivo experiments, C57BL/6 mice were vaccinated subcutaneously with matured, loaded mature DC. Immune response was evaluated through immunohistochemistry and cytometric bead array. Results: Based on the existing protocols for DC generation, therapeutic vaccination of tumor-bearing mice with mature ID8-fLuc Hyp-PDT DC induces an immunogenic response, but provides no survival benefit. As loading with Hyp-PDT lysate induces partial primary maturation, we reduced the dose of LPS to 0.125 μg/ml and the duration of maturation to 6 hours, improving viability of mature DC. Conclusion: We optimized Hyp-PDT-based ID8-fLuc DC vaccine by reducing the amount of LPS and the duration of maturation.